Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

News and Trends 29 Aug 2016

Sanofi’s Phase III Results could make Praluent the next Blockbuster Cholesterol Drug

If you’re only just recovering from Pfizer’s inescapable ad campaign for Lipitor, brace yourself: Sanofi and Regeneron are poised to introduce its successor, Praluent (alirocumab), following its excellent Phase III results. Heart disease is the leading cause of death in Americans over the age of 35, and it contributes significantly to the global mortality rate. […]

August 29, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 29 Aug 2016

Maybe you don’t need Chemo: NEJM hails MammaPrint as Diagnostic Tool

About 46% of women with breast cancer may not need chemotherapy. An article in the New England Journal of Medicine describes a new assay from Agendia, MammaPrint, could save them the pain of this toxic treatment. Personalizing medicine is a major focus in the development of ever more precise treatments, and it is particularly relevant […]

August 29, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 27 Aug 2016

European BioArtists featured in Online Exhibition by Pioneering New York Platform

SciArt Center, a New York-based organisation for the collaboration of scientists and artists on all manner of endeavours, has just opened an online exhibition of bioart featuring a number of European artists. The exhibit, titled, “EmBodied,” explores the understanding of our souls through the human body. The human body is the best picture to the […]

August 27, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 26 Aug 2016

US Money Magnet get hands on UK Bispecific Antibodies for Neurodegenerative Disease

F-star’s “plug-and-play” technology can turn any existing antibody into a full-size bispecific antibody. Denali has recognized its potential use for drug delivery to the CNS and inked a deal with the UK-based company for almost €1B. Denali (US) and F-Star (UK) have struck a deal to develop F-star’s Modular Antibody Technology™ for the generation of […]

August 26, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Aug 2016

Antibodyomes for faster Discovery of Biologicals, with Memo Therapeutics

After delighting ourselves with fabulous French gastronomy in Nancy, it’s time to say our farewells and head to the next border. Basel is our final destination. Our goal? Get to know a bit more of Swiss-based company Memo Therapeutics, our Biotech of the Week. City: Basel, Switzerland Founded: 2010 Employees: 10 Financial Data: €2.1M Total Raised (as of […]

August 26, 2016 - 1 minutemin - By Joachim Eeckhout

News and Trends 26 Aug 2016

UCL & Cell Medica start a TCR Collaboration towards a Cancer Cure

Bridging the divide between academia and industry, Cell Medica and UCL are teaming up on TCR engineering in the effort to find a cancer cure. Not many details were disclosed, but cancer now has a new force to reckon with. For the most part, scientists thrive on competition, and what better fuel is there than […]

August 26, 2016 - 2 minutesmins - By Evelyn Warner

ADVERTISEMENT

News and Trends 25 Aug 2016

Daratumumab could Knock Multiple Myeloma Down and Out: EMA will Judge

Multiple Myeloma is almost a death sentence: you probably won’t make it through five more years, and even if current treatments send it to remission, your chances of relapse are high. Janssen’s new drug, Darzalex (daratumumab), has shown promise to knock MM down and out for good in Phase III trails, and it now awaits […]

August 25, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 25 Aug 2016

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis. Phase III trials have officially begun! Galapagos is making progress as its rheumatoid arthritis drug, filgotinib, enters Phase III clinical trials. This comes after a major setback when its deal with AbbVie fell through last fall. It’s not […]

August 25, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 24 Aug 2016

While working on its HIV Cure, Gilead gives Europe an ‘HIV Vaccine’

Despite progress in HIV treatments and towards an HIV cure, the infection rate has risen to unprecedented levels in Europe. Gilead’s HIV-1 ‘vaccine’, Truvada, has just been approved for marketing in Europe to stop its spread. The year 2014 brought the highest number of new HIV diagnoses ever recorded in Europe, 94% of which were […]

August 24, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 23 Aug 2016

€350M CRISPR Joint Venture now has a Name and an Office

Bayer and CRISPR Therapeutics have invested $373M in a joint venture, Casebia, as the latest effort to bring the revolutionary gene editing technology to the medical market. This brainchild represents a huge leap of faith, since no preliminary results have been revealed. The Boston launch may accelerate its progress through clinical trials and produce the first […]

August 23, 2016 - 3 minutesmins - By Evelyn Warner

Accelerators And Biotech Startups cover

In Depth 23 Aug 2016

5 Expert Tips to Success When Building a Biotech Startup

Succeeding as an entrepreneur is tough, you will have to deal with failure and learn from it along the way. Many new biotech startups face similar problems during their early steps, here are some expert tips on how to avoid them. Last week, I had the opportunity to meet Mark Hammond and Dominic Falcao, who […]

August 23, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Aug 2016

Sanofi loses lead on new Diabetes drug, because of… an user-unfriendly Pen

Sanofi and Novo Nordisk have been in a tight race to put their new insulin GLP-1 combination drugs for Type 2 Diabetes on the market. Sanofi now suffers a short (but critical) setback, as the FDA is not impressed with its drug delivery system. Sanofi and Novo Nordisk have both strong positions in the diabetes […]

August 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT